Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MG-GDX19
- Development stage
- Preclinical
- Lead developer
- MEPSGEN
- Modality
- Nanoparticles → Drug Delivery Systems
01
Overview
MG-GDX19 is a nanomedicine candidate being developed by MEPSGEN for the treatment of medulloblastoma. It is part of the company's MG-X_Nanomedicine pipeline, which utilizes a proprietary biomimetic nanoparticle platform designed to facilitate the delivery of therapeutic agents across the blood-brain barrier (BBB). The drug is currently in the discovery stage of development. MEPSGEN leverages its specialized microvortex technology (MST-X) and NanoCalibur synthesis system to produce these standardized, scalable nanocarriers, aiming to improve therapeutic efficacy and reduce systemic toxicity for patients with brain tumors.
Beyond the preview
Go deeper on MG-GDX19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MG-GDX19.